ArticleBritish journal of cancer2024

Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

Theodora A Constantin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.